ScreenerHero

UCB UCB SA

EBR · BE · Healthcare · Biotechnology · ucb.com
203.40EUR+1.24%Mkt Cap: 41.63B $P/E: 17.75

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn'…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.54BUSDP/E 29.3
MRNA
Moderna, Inc.
$81.13BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$74.79BUSDP/E 18.0
ARGX
argenx SE
$57.11BUSDP/E 34.8
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc.
$44.51BUSD
ONC
BeOne Medicines AG
$41.14BUSDP/E 64.7
RPRX
Royalty Pharma plc
$32.74BUSDP/E 30.1
ALNY
Alnylam Pharmaceuticals, Inc.
$29.42BUSDP/E 37.1
ROIV
Roivant Sciences Ltd.
$25.84BUSD
BNTX
BioNTech SE
$24.53BUSD
GMAB
Genmab A/S
$24.01BUSDP/E 30.3
INCY
Incyte Corporation
$23.13BUSDP/E 14.5
INSM
Insmed Incorporated
$22.67BUSD
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
JAZZ
Jazz Pharmaceuticals plc
$15.32BUSDP/E 16.2
ASND
Ascendis Pharma A/S
$15.01BUSDP/E 17.5
EXEL
Exelixis, Inc.
$14.58BUSDP/E 18.6
SMMT
Summit Therapeutics Inc.
$13.78BUSD
TWST
Twist Bioscience Corporation
$13.59BUSD

Key Statistics

Company
Market Cap41.63B USD
Enterprise Value45.41B USD
Revenue (TTM)9.27B USD
Gross Profit6.25B USD
Net Income (TTM)1.69B USD
Revenue/Share44.77 EUR
Last Price203.40 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees9.0K
CountryBE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)17.75
P/E (Forward)14.79
PEG1.07
EV/EBITDA12.50
EV/Revenue4.90
P/S4.57
P/B3.34
EPS (TTM)11.32
EPS (Forward)13.81
52W Range
200.204% of range289.50
52W High289.50 EUR
52W Low200.20 EUR
Profitability
Gross Margin74.29%
Oper. Margin33.33%
EBITDA Margin39.21%
Profit Margin20.13%
ROE14.34%
ROA8.58%
Growth
Revenue Growth22.50%
Earnings Growth134.80%
Cash Flow & Leverage
Operating CF2.49B USD
CapEx (TTM)488.04M USD
FCF Margin12.88%
FCF Yield2.87%
Net Debt3.07B USD
Net Debt/EBITDA0.84
Balance Sheet
Debt/Equity0.21
Current Ratio1.20
Quick Ratio0.72
Book Value/Sh61.12 EUR
Cash/Share4.02 EUR
Dividends
Fwd Div Rate1.45 EUR
Trail. Div Rate1.45 EUR
Div. Yield0.71%
5Y Avg Yield0.97%
Payout Ratio12.81%
Ex-Div DateMay 4, 2026
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)285.00 EUR
Upside (mean)+40.1%
Target Range208.00 EUR – 340.00 EUR
208.00+40.1% to mean340.00
# Analysts19
Ownership
Shares Out.190.66M
Float120.16M
Insiders36.28%
Institutions39.53%
Technical
SMA 50217.17 (-6.3%)
SMA 200244.18 (-16.7%)
Beta0.18
S&P 52W Chg14.58%
Avg Vol (30d)246.75K
Avg Vol (10d)263.34K
Technical Indicators
RSI (14)36.7
MACD-3.7405
MACD Signal-3.4531
MACD Hist.-0.2874
BB Upper216.11 EUR
BB Middle207.82 EUR
BB Lower199.53 EUR
BB Width7.98%
ATR (14)5.561 EUR
Vol Ratio (20d)0.61x